Efficacy and Safety of Interferon Alpha 2A and Pegylated Interferon Alpha 2A in Inflammatory Macular Edema.

Abstract

Purpose: The aim of this study was to further explore the efficacy and safety of interferon-α in refractory non-infectious inflammatory macular edema and to compare interferon-α2a and pegylated interferon-α2b.Methods: 34 patients with refractory non-infectious uveitic macular edemaunder interferon-α were retrospectively reviewed.Results: Mean baseline best-corrected visual acuityimproved from 0.55 logMar to 0.37 logMAR (P < 0.001) at month (M) 1 and 0.40 logMAR (P < 0.001) at M6. The mean baseline CMT decreased from 554 µm to 367 µm (P < 0.001) at M1 and 394 µm (P < 0.001) at M6. Clinical adverse effects (AEs) were observed in a third of patients, leading to treatment discontinuation because of frequent mild AEs and few severe AE. No statistically significant difference was found between both molecules.Conclusions: Anatomically and functionally, interferon-α was rapidly effective despite a low dosage regimen and no difference in efficacy and tolerance was observed between interferon-α2a and pegylated interferon-α2b.

• Authors: Chloé Couret, Marion Servant, Pierre Lebranchu, Mohamed Hamidou, Michel Weber
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 28 Issue 2 Pg. 329-336 ( 2020) ISSN: 1744-5078 [Electronic] England
• PMID: 31821064 (Publication Type: Journal Article)

Chemical References

• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• peginterferon alfa-2a

Topics

• Adult
• Aged
• Aged, 80 and over
• Female
• Follow-Up Studies
• Humans
• Injections, Subcutaneous
• Interferon-alpha (administration & dosage)
• Macular Edema (diagnosis, drug therapy, etiology)
• Male
• Middle Aged
• Polyethylene Glycols (administration & dosage)
• Recombinant Proteins (administration & dosage)
• Retrospective Studies
• Tomography, Optical Coherence (methods)
• Treatment Outcome
• Uveitis (complications, diagnosis)
• Visual Acuity
• Young Adult